MX2007014444A - Derivados de oxadiazol sustituido como moduladores aloestericos positivos de los receptores de glutamato metabotropicos. - Google Patents
Derivados de oxadiazol sustituido como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.Info
- Publication number
- MX2007014444A MX2007014444A MX2007014444A MX2007014444A MX2007014444A MX 2007014444 A MX2007014444 A MX 2007014444A MX 2007014444 A MX2007014444 A MX 2007014444A MX 2007014444 A MX2007014444 A MX 2007014444A MX 2007014444 A MX2007014444 A MX 2007014444A
- Authority
- MX
- Mexico
- Prior art keywords
- oxadiazole derivatives
- metabotropic glutamate
- positive allosteric
- glutamate receptors
- allosteric modulators
- Prior art date
Links
- 150000004866 oxadiazoles Chemical class 0.000 title abstract 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0510138A GB0510138D0 (en) | 2005-05-18 | 2005-05-18 | Novel compounds A4 |
| GBGB0601709.9A GB0601709D0 (en) | 2006-01-27 | 2006-01-27 | Novel compounds A4 |
| PCT/IB2006/001881 WO2006123255A2 (en) | 2005-05-18 | 2006-05-17 | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007014444A true MX2007014444A (es) | 2008-04-21 |
Family
ID=37431638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007014444A MX2007014444A (es) | 2005-05-18 | 2006-05-17 | Derivados de oxadiazol sustituido como moduladores aloestericos positivos de los receptores de glutamato metabotropicos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090215822A1 (enExample) |
| EP (1) | EP1893606A2 (enExample) |
| JP (1) | JP2008540635A (enExample) |
| KR (1) | KR20080027463A (enExample) |
| AU (1) | AU2006248655A1 (enExample) |
| BR (1) | BRPI0611423A2 (enExample) |
| CA (1) | CA2608014A1 (enExample) |
| EA (1) | EA015813B1 (enExample) |
| IL (1) | IL187186A0 (enExample) |
| MX (1) | MX2007014444A (enExample) |
| NO (1) | NO20076478L (enExample) |
| NZ (1) | NZ564254A (enExample) |
| WO (1) | WO2006123255A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510140D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B2 |
| GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
| GB0622202D0 (en) * | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
| TWI417100B (zh) | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途 |
| TW200911255A (en) | 2007-06-07 | 2009-03-16 | Astrazeneca Ab | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 |
| SA109300358B1 (ar) | 2008-06-06 | 2012-11-03 | استرازينيكا ايه بي | مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| WO2010098866A1 (en) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors |
| WO2010124055A1 (en) * | 2009-04-23 | 2010-10-28 | Merck Sharp & Dohme Corp. | 2-alkyl piperidine mglur5 receptor modulators |
| CA2784830C (en) | 2009-12-18 | 2018-03-27 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| CN102762572A (zh) | 2010-02-01 | 2012-10-31 | 诺瓦提斯公司 | 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| EP2531490B1 (en) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexyl amide derivatives as crf receptor antagonists |
| US20130210804A1 (en) * | 2010-10-25 | 2013-08-15 | Neville J. Anthony | Tricyclic mglur5 receptor modulators |
| WO2016065584A1 (en) * | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Piperidine oxadiazole and thiadiazole orexin receptor antagonists |
| EP3275440B1 (en) * | 2015-03-25 | 2022-05-04 | National Center for Geriatrics and Gerontology | Novel oxadiazole derivative and pharmaceutical containing same |
| WO2022069953A1 (en) * | 2020-09-29 | 2022-04-07 | Ranjith Siddaraj | Synthesis and characterization of (s)-3-(5- fluoropyridin-2-yl)-5-(piperidin-3-yl)-l,2,4-oxadiazole derivatives and their secretory phospholipase a2 (spla2) inhibitor activity |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966748A (en) * | 1975-05-08 | 1976-06-29 | American Cyanamid Company | Para-fluorophenyl-N-heterocyclic substituted butanes |
| CN1691944A (zh) * | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体－5调节剂的噁二唑 |
| JP2006522128A (ja) * | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−５のモジュレーターとしての４環イミダゾール誘導体 |
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| SG149900A1 (en) * | 2004-02-18 | 2009-02-27 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| GB0510143D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| GB0510140D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B2 |
| GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0622202D0 (en) * | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
-
2006
- 2006-05-17 WO PCT/IB2006/001881 patent/WO2006123255A2/en not_active Ceased
- 2006-05-17 BR BRPI0611423-7A patent/BRPI0611423A2/pt not_active IP Right Cessation
- 2006-05-17 JP JP2008511821A patent/JP2008540635A/ja active Pending
- 2006-05-17 EP EP06779843A patent/EP1893606A2/en not_active Withdrawn
- 2006-05-17 CA CA002608014A patent/CA2608014A1/en not_active Abandoned
- 2006-05-17 MX MX2007014444A patent/MX2007014444A/es not_active Application Discontinuation
- 2006-05-17 US US11/920,603 patent/US20090215822A1/en not_active Abandoned
- 2006-05-17 EA EA200702469A patent/EA015813B1/ru not_active IP Right Cessation
- 2006-05-17 KR KR1020077029359A patent/KR20080027463A/ko not_active Ceased
- 2006-05-17 NZ NZ564254A patent/NZ564254A/en not_active IP Right Cessation
- 2006-05-17 AU AU2006248655A patent/AU2006248655A1/en not_active Abandoned
-
2007
- 2007-11-06 IL IL187186A patent/IL187186A0/en unknown
- 2007-12-17 NO NO20076478A patent/NO20076478L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006123255A2 (en) | 2006-11-23 |
| EP1893606A2 (en) | 2008-03-05 |
| IL187186A0 (en) | 2008-02-09 |
| KR20080027463A (ko) | 2008-03-27 |
| AU2006248655A1 (en) | 2006-11-23 |
| JP2008540635A (ja) | 2008-11-20 |
| WO2006123255A3 (en) | 2007-03-29 |
| EA200702469A1 (ru) | 2008-06-30 |
| CA2608014A1 (en) | 2006-11-23 |
| NZ564254A (en) | 2011-04-29 |
| EA015813B1 (ru) | 2011-12-30 |
| US20090215822A1 (en) | 2009-08-27 |
| BRPI0611423A2 (pt) | 2010-09-08 |
| NO20076478L (no) | 2008-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007014405A (es) | Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos. | |
| ZA200710279B (en) | Pyrrole derivatives as positive allosteric modulators of metabotropic glutamate receptors | |
| UA87856C2 (ru) | Алкильные производные как модуляторы метаботропных рецепторов глутамата | |
| UA83257C2 (en) | Allosteric modulators of metabotropic glutamate receptors | |
| DE602005025672D1 (de) | Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren | |
| WO2006123255A3 (en) | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors | |
| MX2007014400A (es) | Novedosos compuestos heterociclicos como moduladores aloestericos positivos de los receptores de glutamato metabotropicos. | |
| IL189298A0 (en) | 3.5-disubstituted phenyl-piperidines as modulators of dopamine meurotransmission | |
| ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
| DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| HK1110852A (en) | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors | |
| UA92495C2 (ru) | Замещенные производные оксадиазола как положительные аллостерические модуляторы метаботропных глутаматных рецепторов | |
| HK1110076A (en) | Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | |
| ATE479691T1 (de) | 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren | |
| ATE502947T1 (de) | 4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren | |
| MXPA06013945A (es) | Piperidinas sustituidas, novedosas, como moduladores de la neurotransmision de dopamina. | |
| HK1111148A (en) | Novel heterocyclic compounds as positive allosteric modulators of metabotropic glutamate receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |